FDA widens a myasthenia gravis drug's label to patients a blood test used to exclude

The FDA on 8 May approved an expanded label for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), extending their use in generalized myasthenia gravis (gMG) to adults regardless of antibody status — including a subset of patients who, until now, had no antibody-targeted treatment option at all [s1].

The gap the approval closes

Myasthenia gravis is usually diagnosed by detecting antibodies against the acetylcholine receptor (AChR), and Vyvgart's original approval, like most gMG drugs developed in the past decade, covered only patients who test positive for those antibodies. But roughly 20% of people with generalized myasthenia gravis do not have detectable AChR antibodies, according to James F. Howard Jr., M.D., a professor of neurology at the University of North Carolina at Chapel Hill School of Medicine, who was quoted in argenx's announcement [s1]. Some of those patients instead test positive for antibodies against MuSK or LRP4, while others — described as "triple seronegative" — test negative across all three. Dr. Howard said that population "were rarely included in clinical trials" prior to this study, which has made diagnosis and management "especially difficult" [s1].

The newly approved indication extends to all four groups: AChR-antibody positive, MuSK-antibody positive, LRP4-antibody positive, and triple seronegative — making Vyvgart and Vyvgart Hytrulo, per argenx, "the first and only approved treatments for all serotypes of adult patients living with gMG" [s1].

What the trial showed

The approval is based on the Phase 3 ADAPT SERON study, which argenx describes as the largest study to date of gMG patients without detectable AChR antibodies, spanning the three non-AChR serotypes [s1]. The trial met its primary endpoint, showing a statistically significant improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living) score compared with placebo at four weeks (p=0.0068) [s1]. Across the overall study population, the mean improvement in MG-ADL score from baseline was 3.35 points at week 4 [s1]. Patients across all three serotypes — MuSK-positive, LRP4-positive and triple seronegative — showed clinically meaningful gains, and argenx says those improvements were "rapid, significant and sustained" with continued treatment, covering symptoms including speech, vision, physical function and swallowing [s1]. The company also reports the safety profile was consistent with what had already been established in AChR-positive patients [s1].

Why the mechanism travels across antibody types

Vyvgart works by blocking the neonatal Fc receptor (FcRn), which lowers circulating levels of immunoglobulin G (IgG) antibodies broadly — not by targeting the AChR antibody specifically. That mechanism is why argenx and outside researchers believed the drug could plausibly help seronegative and non-AChR patients too, whose disease is thought to still be antibody-driven even when the standard AChR test comes back negative. The ADAPT SERON results are the clinical confirmation of that reasoning rather than a change in how the drug itself works.

Luc Truyen, M.D., Ph.D., argenx's chief medical officer, framed the approval as removing a diagnostic bottleneck from treatment decisions: "Today's approval means that all adult gMG patients, regardless of serotype, can now benefit from VYVGART's rapid onset, sustained disease control, and favorable safety profile," he said. "For clinicians, this simplifies treatment decisions, representing a major advancement in reaching as many patients living with gMG as possible" [s1].

What is still unresolved

argenx's own announcement frames this as "the broadest MG label to date" [s1] — a description that is true only relative to Vyvgart's competitors, all of which remain restricted to AChR-positive patients. The company's release does not disclose the ADAPT SERON trial's total enrollment size, its placebo response rate, or a breakdown of results by each of the three individual seronegative subgroups beyond the qualitative description that "clinically meaningful improvements" occurred "across all three." Nor does it specify a duration for the "sustained" improvements it describes beyond the four-week primary endpoint. Prescribers evaluating the drug for a newly-eligible seronegative patient will be working from the FDA-approved label and the underlying trial publication, once available, rather than the top-line company summary.

What to watch

Whether payers extend the same coverage terms to the newly eligible seronegative population that AChR-positive patients already receive, since insurance authorization for gMG treatments has historically leaned on the antibody test result as a gatekeeping criterion. And whether full results from ADAPT SERON — including durability data beyond four weeks and outcomes broken out by the three non-AChR subgroups — are published in a peer-reviewed journal, which would allow independent scrutiny of the efficacy claims beyond what the approval announcement discloses.

Sources

• [s1] argenx SE, "argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG," 8 May 2026. https://www.globenewswire.com/news-release/2026/05/08/3291372/0/en/argenx-announces-u-s-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adult-patients-living-with-gmg.html